| 指标 | 大博医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 207.18亿元 | 115.61亿元 | 12 124 | | 净资产 | 34.37亿元 | 38.93亿元 | 43 124 | | 净利润 | 4.25亿元 | 2.11亿元 | 17 124 | | 市盈率(动) | 36.59 | 62.61 | 37 124 | | 市净率 | 6.21 | 3.93 | 109 124 | | 毛利率 | 71.23% | 51.22% | 16 124 | | 净利率 | 23.92% | 9.57% | 26 124 | | ROE | 12.83% | 0.15% | 7 124 | 证券之星消息，截至2025年10月31日收盘，大博医疗(002901)报收于50.04元，上涨1.38%，换手率 1.58%，成交量4.55万手，成交额2.28亿元。 10月31日的资金流向数据方面，主力资金净流出14.64万元，占总成交额0.06%，游资资金净流入 1253.59万元，占总成交额5.5%，散户资金净流出1238.94万元，占总 ...

大博医疗10月31日大宗交易平台出现一笔成交，成交量196.80万股，成交金额9052.80万元，大宗交易成 交价为46.00元，相对今日收盘价折价8.07%。该笔交易的买方营业部为中信证券股份有限公司厦门分公 司，卖方营业部为中信证券股份有限公司厦门分公司。 证券时报•数据宝统计显示，大博医疗今日收盘价为50.04元，上涨1.38%，日换手率为1.58%，成交额为 2.28亿元，全天主力资金净流入362.75万元，近5日该股累计下跌5.26%，近5日资金合计净流出1.14万 元。 两融数据显示，该股最新融资余额为1.62亿元，近5日增加2526.45万元，增幅为18.51%。 据天眼查APP显示，大博医疗科技股份有限公司成立于2004年08月12日，注册资本41401.9506万人民 币。（数据宝） 10月31日大博医疗大宗交易一览 | 成交量 | 成交金 额 | 成交价 | 相对当日 | | | | --- | --- | --- | --- | --- | --- | | | | 格 | 收盘折溢 | 买方营业部 | 卖方营业部 | | （万 股） | （万 | （元） | 价 | | | | | 元） ...

| 成交量(万 | 成交金额(万 | 成交价格 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | | | | | | | 中信证券股份有限公司厦门分 | 中信证券股份有限公司厦门分 | | 196.80 | 9052.80 | 46.00 | 公司 | | | | | | | 公司 | （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 大博医疗10月31日大宗交易平台共发生1笔成交，合计成交量196.80万股，成交金额9052.80万元。成交 价格平均为46.00元，相对今日收盘价折价8.07%。 10月31日大博医疗大宗交易一览 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 ...

证券日报网讯大博医疗10月31日在互动平台回答投资者提问时表示，公司2025年第三季度实现营收6.66 亿元，同比增长17.82%；实现归母净利润1.8亿元，同比增长77.49%。 （文章来源：证券日报） ...

近三个月该股共发生1笔大宗交易，合计成交1.97万手，折价成交1笔。该股近期无解禁股上市。 大宗交易成交价格46元，相对当日收盘价折价8.07%，成交196.8万股，成交金额9052.8万元，买方营业 部为中信证券股份有限公司厦门分公司，卖方营业部为中信证券股份有限公司厦门分公司。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年10月31日收盘，大博医疗(002901)报收于50.04元，上涨1.38%，换手率1.58%，成交量4.55万 手，成交额2.28亿元。 证券之星消息，10月31日大博医疗发生大宗交易，交易数据如下： 该股最近90天内共有1家机构给出评级，买入评级1家。 ...

天眼查App显示，近日，厦门福创大博医疗产业创业投资合伙企业（有限合伙）成立，执行事务合伙人 为福建省创新创业投资管理有限公司，出资额3亿人民币，经营范围为创业投资。合伙人信息显示，该 企业由福建省投资开发集团有限责任公司、广西大博商通创业投资有限公司、厦门海沧产业发展股权投 资合伙企业（有限合伙）、福建省创新创业投资管理有限公司共同出资。 天眼查App显示，近日，厦门福创大博医疗产业创业投资合伙企业（有限合伙）成立，执行事务合伙人 为福建省创新创业投资管理有限公司，出资额3亿人民币，经营范围为创业投资。 ...

交易信息汇总 截至2025年10月30日收盘，大博医疗(002901)报收于49.36元，下跌7.2%，换手率1.96%，成交量5.66万 手，成交额2.85亿元。 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：大博医疗股价连续2日下跌，10月30日收盘报49.36元，跌幅7.2%。 来自交易信息汇总：近10个交易日主力资金累计净流出2453.83万元，同期股价累计下跌9.73%。 来自交易信息汇总：10月30日主力资金净流出1409.55万元，散户与游资资金分别净流入615.62万 元和793.92万元。 10月30日大博医疗（002901）收盘报49.36元，跌7.2%，当日成交566.13万元。该股已连续2日下跌。前 10个交易日主力资金累计净流出2453.83万元，股价累计下跌9.73%；融资余额累计减少1113.82万元， 融券余量累计增加1000股。最近90天内共有1家机构给出评级，均为买入评级。 资金流向方面，10月30日主力资金净流出1409.55万元，游资资金净流入793.92万元， ...

证券之星消息，10月30日医疗器械板块较上一交易日下跌1.9%，大博医疗领跌。当日上证指数报收于 3986.9，下跌0.73%。深证成指报收于13532.13，下跌1.16%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002950 | 奥美医疗 | 11.03 | 9.97% | 19.60万 | 2.14亿 | | 688656 | 浩欧博 | 158.00 | 5.93% | 1.37万 | 2.14亿 | | 301087 | 可孚医疗 | 45.70 | 4.94% | 6.58万 | 3.06亿 | | 300453 | 三鑫医疗 | 9.47 | 3.38% | 18.99万 | 1.80亿 | | 605369 | 共东医疗 | 19.38 | 2.65% | 3.62万 | 6875.72万 | | 920925 | 锦好医疗 | 34.85 | 2.50% | 2.27万 | 7836.02万 | | 920300 | 辰光医疗 | 18.3 ...

Group 1 - Chuanfa Longmang's wholly-owned subsidiary plans to invest 660 million yuan to establish a joint venture for a 175,000 tons/year high-pressure lithium iron phosphate project in Sichuan Mianzhu, with a total investment of 1.961 billion yuan [1] - The joint venture will be co-owned by Jiangxi Shenghua New Materials (51%) and Deyang Chuanfa Longmang (49%) [1] - Chuanfa Longmang specializes in the production and sales of various phosphate products, including lithium iron phosphate [1] Group 2 - Sino Medical's COMETIU self-expanding intracranial drug-coated stent system registration application was not approved by the National Medical Products Administration [2] - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices [3] Group 3 - Jincheng Pharmaceutical's subsidiaries have been selected for the 11th batch of national drug centralized procurement [3] - Jincheng Pharmaceutical is engaged in the research, development, production, and sales of pharmaceutical intermediates and formulations [3] Group 4 - Zhongke Lanyun reported a 4.29% increase in revenue to 1.302 billion yuan and a 2.17% increase in net profit to 211 million yuan for the first three quarters [4] - The company specializes in wireless audio SoC chip research, design, and sales [5] Group 5 - Dabo Medical achieved a 22.69% increase in revenue to 1.876 billion yuan and a 77.03% increase in net profit to 425 million yuan for the first three quarters [6] - Dabo Medical focuses on the production, research, and sales of high-value medical consumables [7] Group 6 - Dayang Electric reported a 3.81% increase in revenue to 9.180 billion yuan and a 25.95% increase in net profit to 845 million yuan for the first three quarters [8][9] - The company operates in the electric motor sector, focusing on building and home appliance motors and automotive components [9] Group 7 - Fudan Microelectronics reported a 12.70% increase in revenue to 3.024 billion yuan but a 22.69% decrease in net profit to 330 million yuan for the first three quarters [10][11] - The company specializes in the design, development, and testing of large-scale integrated circuits [11] Group 8 - Shaanxi Energy reported a 2.83% decrease in revenue to 16.359 billion yuan and a 3.23% decrease in net profit to 2.417 billion yuan for the first three quarters [12][13] - The company is involved in thermal power generation and coal production and sales [13] Group 9 - Runhe Software reported a 12.86% increase in revenue to 2.719 billion yuan but a 29.01% decrease in net profit to 78.57 million yuan for the first three quarters [14][15] - The company focuses on financial technology, smart IoT, and smart energy [15] Group 10 - Shenzhen Gas reported an 8.63% increase in revenue to 22.528 billion yuan but a 13.08% decrease in net profit to 918 million yuan for the first three quarters [16][17] - The company specializes in urban gas supply and comprehensive energy services [17] Group 11 - Light Media reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% increase in net profit to 2.336 billion yuan for the first three quarters [18][19] - The company is engaged in the investment, production, and distribution of film projects [19] Group 12 - Dazhong Mining's subsidiary obtained a mining license for the Hunan Jijiao Mountain lithium mine, with a resource amount of 490 million tons, equivalent to approximately 3.2443 million tons of lithium carbonate [19] - The company specializes in iron ore mining and production [19] Group 13 - Yirui Technology reported a 14.22% increase in revenue to 1.549 billion yuan and a 20.61% increase in net profit to 471 million yuan for the first three quarters [20] - The company focuses on the research, production, and sales of digital X-ray detectors and related solutions [20] Group 14 - TCL Zhonghuan reported a 4.48% decrease in revenue to 121.572 billion yuan and a net loss of 5.777 billion yuan for the first three quarters [21][22] - The company specializes in the research, production, and sales of photovoltaic silicon wafers, cells, and modules [22] Group 15 - Huangshan Tourism reported an 8.75% increase in revenue to 1.535 billion yuan but an 11.02% decrease in net profit to 253 million yuan for the first three quarters [23][24] - The company provides tourism and leisure services [24] Group 16 - Mountain Outside Mountain reported a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 105 million yuan for the first three quarters [25][26] - The company specializes in the research, production, and sales of blood purification equipment and services [26] Group 17 - Huajin Capital reported a 16.36% increase in revenue to 349 million yuan and a 185.62% increase in net profit to 104 million yuan for the first three quarters [27] - The company focuses on investment management and electronic device manufacturing [27] Group 18 - Datang Power reported a 1.82% decrease in revenue to 89.345 billion yuan but a 51.48% increase in net profit to 6.712 billion yuan for the first three quarters [28][29] - The company primarily engages in thermal power generation [29] Group 19 - Datang Power announced the acquisition of a 50% stake in Anhui Electric Power for 1 yuan, which will result in full ownership of Anhui Electric Power [30] - The company focuses on thermal power generation [30] Group 20 - Kairun Co. reported a 22.94% increase in revenue to 3.719 billion yuan but a 13.38% decrease in net profit to 278 million yuan for the first three quarters [31] - The company specializes in the research, design, production, and sales of leisure bags and related products [31] Group 21 - Dafu Technology reported a 1.95% increase in revenue to 1.764 billion yuan but a net loss of 170 million yuan for the first three quarters [32] - The company focuses on the research, production, and sales of RF products and automotive components [32] Group 22 - Dafu Technology plans to publicly transfer 49% of its stake in Dasheng Graphite [34] - The company specializes in the research, production, and sales of RF products and automotive components [34]

公募基金方面，本期较上一期持股增加的公募基金共计1个，即南方中证1000ETF，持股增加占比小幅 上涨。本期较上一季度持股减少的公募基金共计4个，包括博时医疗保健混合A、博时健康成长双周定 期可赎回混合A、大成品质医疗股票A、博时健康生活混合A，持股减少占比达0.38%。本期较上一季度 新披露的公募基金共计2个，包括招商核心优选A、中信保诚惠泽18个月定开债券A。本期较上一季未再 披露的公募基金共计98个，主要包括华夏中证1000ETF、大成多策略混合(LOF)A、广发中证1000ETF、 工银养老产业股票A、南方医药保健灵活配置混合A等。 外资态度来看，本期较上一期持股增加的外资基金共计1个，即香港中央结算有限公司，持股增加占比 达1.61%。 2025年10月29日，大博医疗(002901.SZ)发布2025年第三季报。截至2025年10月28日，共有10个机构投 资者披露持有大博医疗A股股份，合计持股量达1.96亿股，占大博医疗总股本的47.30%。其中，前十大 机构投资者包括广西大博商通创业投资有限公司、大博醫療國際投資有限公司、香港中央结算有限公 司、中国银行股份有限公司-博时医疗保健行业混合型证券 ...